Notification of Preliminary Results

RNS Number : 6485I

ReNeuron Group plc

03 June 2014

 

3 June 2014

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or "the Company")

Notification of Preliminary Results

Guildford, UK, 3 June 2014: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, will announce its preliminary results for the year ended 31 March 2014 on Wednesday 18 June 2014.

A meeting for analysts will be held at 10.00am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 10.00am on the day of the results: http://mediaserve.buchanan.uk.com/2014/reneuron180614/registration.asp 

A recording of the presentation will be made available on ReNeuron's and Buchanan's websites, www.reneuron.com and www.buchanan.uk.com.

Enquiries:

ReNeuron                                                                                [phone]

Michael Hunt, Chief Executive Officer

Dr John Sinden, Chief Scientific Officer

Richard Moulson, Interim CFO

Buchanan                                                                                  [phone]

Mark Court, Fiona Henson, Sophie Cowles                                                          

Cenkos Securities                                                                    [phone]

Stephen Keys, Dr Christopher Golden (NOMAD and Broker)

Andy Roberts (Sales)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development business.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. 

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

NORSSUFMEFLSELM